Quercetin inhibits a large panel of kinases implicated in cancer cell biology

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 833-842

  Boly, Rainatou ^a,b   Gras, Thierry ^a   Lamkami, Touria ^a   Guissou, Pierre ^b   Serteyn, Didier ^c   Kiss, Robert ^a   Dubois, Jacques ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Agelanthus dodoneifolius; Anticancer activity; Apoptosis resistance; In vitro; Kinases; Quercetin

Indexed keywords

AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; CYCLIN DEPENDENT KINASE 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; JANUS KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; NEK4 PROTEIN; NEK9 PROTEIN; P21 ACTIVATED KINASE 3; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE PIM 1; PROTEIN SERINE THREONINE KINASE; QUERCETIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CYTOTOXICITY; ENZYME INHIBITION; IC 50; MICROSCOPY; MITOSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL BIOLOGY; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; LORANTHACEAE; NEOPLASMS; PHOSPHOTRANSFERASES; PLANT EXTRACTS; QUERCETIN; SIGNAL TRANSDUCTION; SPODOPTERA;

EID: 79952033433     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.890     Document Type: Article

References (63)

1. Newman DJ and Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477, 2007. (Pubitemid 46595760)
2. Liu HL, Jiang WB and Xie MX: Flavonoids: Recent advances as anticancer drugs. Recent Patents Anti-Cancer Drug Discov (In press).
3. Deeni YY and Sadiq NM: Antimicrobial properties and phytochemical constituents of the leaves of African mistletoe (Tapinanthus dodoneifolius (DC) Danser) (Loranthaceae): an ethnomedicinal plant of Hausaland, Northern Nigeria. J Ethnopharmacol 83: 235-240, 2002. (Pubitemid 35339364)
4. Ouedraogo M, Carreyre H, Vandenbrouck C, Bescond J, Raymond G, Guissou IP, Cognard C, Becq F, Potreau D, Couson A, Marrot J and Coustard JM: Structure elucidation of a dihydropyranone from Tapinanthus dodoneifolius. J Nat Prod 70: 2006-2009, 2007.
5. Ren W, Qiao Z, Wang H, Zhu L and Zhang L: Flavonoids: Promising anticancer agents. Med Res Rev 23: 519-534, 2003. (Pubitemid 36706514)
6. Murakami A, Ashida H and Terao J: Multitargeted cancer prevention by quercetin. Cancer Lett 269: 315-325, 2008.
7. Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J and Sachinidis A: Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O- gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem 16: 1451-1462, 2009.
8. Williams RJ, Spencer JP and Rice-Evans C: Flavonoids: antioxidants or signaling molecules? Free Radic Biol Med 36: 838-849, 2004.
9. Lamoral-Theys D, Pottier L, Dufrasne F, Nève J, Dubois J, Kornienko A, Kiss R and Ingrassia L: Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr Med Chem 17: 812-825, 2010.
10. Gilbert ER and Liu D: Flavonoids influence epigenetic-modifying enzyme activity: Structure-function relationships and the therapeutic potential for cancer. Curr Med Chem 17: 1756-1768, 2010.
11. Jeong JH, An JY, Kwon YT, Li LY and Lee YJ: Quercetin-induced ubiquitination and down-regulation of Her-2/neu. J Cell Biochem 105: 585-595, 2008.
12. Hayot C, Farinelle S, De Decker R, Decaestecker C, Darro F, Kiss R and Van Damme M: In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 21: 417-425, 2002.
13. Joseph B, Darro F, Béliard A, Lesur B, Collignon F, Decaestecker C, Frydman A, Guillaumet G and Kiss R: 3-aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo anti-tumor effects with emphasis on a new therapeutical target connected with cell migration. J Med Chem 45: 2543-2555, 2002. (Pubitemid 34595224)
14. Lamoral-Theys D, Andolfi A, Van Goietsenoven G, Cimmino A, Le Calvé B, Wauthoz N, Mégalizzi V, Gras T, Bruyère C, Dubois J, Mathieu V, Kornienko A, Kiss R and Evidente A: Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: An investigation of structure-activity relationship and mechanistic insight. J Med Chem 52: 6244-6256, 2009.
15. Lamoral-Theys D, Pottier L, Kerff F, Dufrasne F, Proutière F, Wauthoz N, Neven P, Ingrassia L, Van Antwerpen P, Lefranc F, Gelbcke M, Pirotte B, Kraus JL, Nève J, Kornienko A, Kiss R and Dubois J: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli. BioOrg Med Chem 18: 3823-3833, 2010.
16. Mijatovic T, Op De Beeck A, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y and Kiss R: The cardenolide UNBS1450 is able to deactivate NF-kappaB-mediated cytoprotective effects in human non-small-cell-lung cancer (NSCLC) cells. Mol Cancer Ther 5: 1-9, 2006.
17. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R and Mathieu V: Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229: 172-183, 2008.
18. Delbrouck C, Doyen I, Belot N, Decaestecker C, Ghanooni R, de Lavareille A, Kaltner H, Choufani G, Danguy A, Vandenhoven G, Gabius HJ, Hassid S and Kiss R: Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration. Lab Invest 82: 147-158, 2002. (Pubitemid 34160452)
19. Lefranc F, James S, Camby I, Gaussin JF, Darro F, Brotchi J, Gabius HJ and Kiss R: Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenograft. J Neurosurg 102: 706-714, 2005. (Pubitemid 43186676)
20. Mégalizzi V, Mathieu V, Mijatovic T, Gailly P, Debeir O, De Neve N, Van Damme M, Bontempi G, Haibe-Kains B, Decaestecker C, Kondo Y, Kiss R and Lefranc F: 4-IBP: a sigma-1 receptor agonist decreases the migration of human cancer cells including glioblastoma cells in vitro and sensitizes them in vitro and in vivo to the cytotoxic insults of proapoptotic and pro-autophagic drugs. Neoplasia 9: 358-369, 2007. (Pubitemid 46799979)
21. +-ATPase) to combat glioblastoma cells. Neurosurgery 62: 211-222, 2008.
22. Agrawal M, Garg RJ, Kanzarjian H and Cortes J: Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the 'best' therapy. Curr Oncol Rep 12: 302-313, 2010.
23. Boss DS, Beijnen JH and Schellens JHM: Clinical experience with Aurora kinase inhibitors: a review. Oncologist 14: 780-793, 2009.
24. Garuti L, Roberti M and Bottegoni G: Small molecule aurora kinase inhibitors. Curr Med Chem 16: 1949-1963, 2009.
25. Collis SJ and Boulton SJ: Emerging links between the biological clock and the DNA damage response. Chromosoma 116: 331-339, 2007. (Pubitemid 46995573)
26. Wiernik PH: FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 8: 429-444, 2010.
27. Hou DX and Kumamoto T: Flavonoids ass protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid Redox Signal 13: 691-719, 2010.
28. Cornejo NG, Boggon TJ and Mercher T: JAK3: a two-faced player in hematological disorders. Int J Biochem Cell Biol 41: 2376-2379, 2009.
29. Canadas I, Rojo F, Arumi-Uria M, Rouira A, Albanell J and Arriola E: cMET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol 12: 253-260, 2010.
30. De Carcer G, Perez de Castro I and Malumbres M: Targeting cell cycle kinases for cancer therapy. Curr Med Chem 14: 969-985, 2007.
31. O'Regan L, Blot J and Fry AM: Mitotic regulation by NIMA-related kinases. Cell Div 2: 25, 2007.
32. Molli PR, Li DQ, Murray BW, Rayala SK and Kumar R: PAK signalling in oncogenesis. Oncogene 28: 2545-2555, 2009.
33. Wells CM and Jones GE: The emerging importance of group II PAKs. Biochem J 425: 465-473, 2010.
34. Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB and Salto-Tellez M: Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer 44: 2144-2151, 2008.
35. Amaravadi R and Thompson CB: The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618-2624, 2005. (Pubitemid 41434384)
36. Wells SA Jr and Santoro M: Targeting the RET pathway in thyroid cancer. Clin Cancer Res 15: 7119-7123, 2009.
37. Cook KM and Figg WD: Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60: 222-243, 2010.
38. Turner N and Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129, 2010.
39. George D: Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 28: 27-33, 2001.
40. Simpson CD, Anyiwe K and Schimmer AD: Anoikis resistance and tumor metastasis. Cancer Lett 272: 177-185, 2008.
41. Savage P, Stebbing J, Bower M and Crook T: Why does cytotoxic chemotherapy cure only some cancers? Nat Clin Pract Oncol 6: 43-52, 2009.
42. Wilson TR, Johnston PG and Longley DB: Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 9: 307-319, 2009.
43. Denlinger CE, Rundall BK and Jones DR: Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-kappaB. Semin Thorac Cardiovasc Surg 16: 28-39, 2004. (Pubitemid 38714757)
44. Han S and Roman J: Targeting apoptotic signalling pathways in human lung cancer. Curr Cancer Drug Targets (In press).
45. Mathieu A, Remmelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, Darro F, Kiss R and Salmon I: Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice. Cancer 101: 1908-1918, 2004.
46. Soengas MS and Lowe SW: Apoptosis and melanoma resistance. Oncogene 22: 3138-3151, 2003.
47. Mathieu V, Pirker C, Martin de Lassalle E, Vernier M, Mijatovic T, DeNeve N, Gaussin JF, Dehoux M, Lefranc F, Berger W and Kiss R: The sodium pumpa alpha-1 subunit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med 13: 3960-3972, 2009.
48. El Maalouf G, Le Tourneau C, Batty GN, Faivre S and Raymond E: Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 35: 167-174, 2009.
49. Wong HH and Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6: 412-422, 2009.
50. D'Amico TA and Harpole DH Jr: Molecular biology of esophageal cancer. Chest Surg Clin N Am 10: 451-469, 2000. (Pubitemid 30627541)
51. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R and Salmon I: Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p/19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95: 641-655, 2002. (Pubitemid 34810191)
52. Lefranc F, Brotchi J and Kiss R: Possible future issues in the treatment of glioblastomas, with a special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23: 2411-2422, 2005. (Pubitemid 46218735)
53. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV and Limtrakul PN: Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64: 573-582, 2002.
54. Mayur YC, Peters GJ, Prasad VV, Lemo C and Sathish NK: Design of new drug molecules to be used in reversing multidrug resistance in cancer cells. Curr Cancer Drug Targets 9: 298-306, 2009.
55. Fedorov O, Müller S and Knapp S: The (un)target cancer kinome. Nat Chem Biol 6: 166-169, 2010.
56. Gossage L and Eisen T: Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 16: 1973-1978, 2010.
57. Knight ZA, Lin H and Shokat KM: Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130-137, 2010.
58. Butt MS and Sultan MT: Green tea: nature's defense against malignancies. Crit Rev Food Sci Nutr 49: 463-473, 2009.
59. Kraft TE, Parisotto D, Schempp C and Efferth T: Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit Rev Food Sci Nutr 49: 782-799, 2009.
60. Liu EH, Qi LW, Wu Q, Peng YB and Li P: Anticancer agents derived from natural products. Mini Rev Med Chem 9: 1547-1555, 2009.
61. Bar-Sela G, Epelbaum R and Schaffer M: Curcumin as an anticancer agent: review of the gap between basic and clinical applications. Curr Med Chem 17: 190-197, 2010.
62. Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger W, Van Quaquebeke E and Kiss R: Structure-activity-relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae Isocarbostyril alkaloid) as potential anti-cancer agents. J Med Chem 52: 1100-1114, 2009.
63. Dumont P, Ingrassia L, Rouzeau S, Ribaucour F, Thomas S, Roland I, Darro F, Lefranc F and Kiss R: The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the Death Receptor and/or the mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 9: 766-776, 2007. (Pubitemid 47523238)